RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome

Steg, P.G.; Mehta, S.R.; Jukema, J.W.; Lip, G.Y.H.; Gibson, C.M.; Kovar, F.; ... ; RUBY-1 Investigators (2011)

Article / Letter to editor

• Anticoagulant
• Acute coronary syndrome
• Secondary prevention
• Darexaban

• All authors: Steg, P.G.; Mehta, S.R.; Jukema, J.W.; Lip, G.Y.H.; Gibson, C.M.; Kovar, F.; Kala, P.; Garcia-Hernandez, A.; Renfurm, R.W.; Granger, C.B.; RUBY-1 Investigators
• Date: 2011-10-31
• Journal: European Heart Journal
• Volume: 32
• Issue: 20
• Pages: 2541 - 2554
• DOI: doi:10.1093/eurheartj/ehr334